North America Nuclear Medicine Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals), By Application (Oncology, Cardiology, Neurology, and Others), and North America Nuclear Medicine Market Insights, Industry Trend, Forecasts to 2035
Industry: Healthcare
North America Nuclear Medicine Market Insights Forecasts to 2035
- The North America Nuclear Medicine Market Size Was Estimated at USD 6.29 Billion in 2024
- The Market Size is Expected to Grow at a CAGR of Around 14.83% from 2025 to 2035
- The North America Nuclear Medicine Market Size is Expected to Reach USD 28.80 Billion by 2035
Get more details on this report -
According to a research report published by Spherical Insights & Consulting, The North America Nuclear Medicine Market Size is anticipated to reach USD 28.80 Billion by 2035, growing at a CAGR of 14.83% from 2025 to 2035.
Market Overview
The nuclear medicine market creates a professional definition which describes the worldwide market that encompasses all activities related to research and development, production and distribution and clinical use of radiopharmaceuticals, which are radioisotope-based pharmaceutical products and their accompanying molecular imaging technologies that include Positron Emission Tomography and Single-Photon Emission Computed Tomography and targeted radionuclide therapies. Radiopharmaceuticals for both diagnostic and therapeutic uses, gamma cameras, cyclotrons, positron emission tomography (PET), and single-photon emission computed tomography (SPECT) are important components of that industry.
In July 2025, Lantheus Holdings launched an expanded nuclear medicine portfolio by acquiring Life Molecular Imaging for up to USD 750 million, securing Neuraceq F-18 PET imaging to advance Alzheimer’s detection and molecular diagnostics. The market for nuclear medicine is fueled by a number of important elements that work together to promote its expansion and uptake in healthcare systems. The need for cutting-edge diagnostic and treatment options has increased due to the rising incidence of chronic and oncological diseases, including cancer, heart disease, and neurological disorders.
Report Coverage
This research report categorizes the market for the North America nuclear medicine market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America nuclear medicine market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the North America nuclear medicine market.
North America Nuclear Medicine Market Report Coverage
| Report Coverage | Details |
|---|---|
| Base Year: | 2024 |
| Market Size in 2024: | USD 6.29 Billion |
| Forecast Period: | 2025-2035 |
| Forecast Period CAGR 2025-2035 : | CAGR of 14.83% |
| 2035 Value Projection: | USD 28.80 Billion |
| Historical Data for: | 2020-2023 |
| No. of Pages: | 210 |
| Tables, Charts & Figures: | 95 |
| Segments covered: | By Product Type, By Application |
| Companies covered:: | Actinium Pharmaceuticals, BWXT Medical, Cardinal Health, Cellectar Biosciences, GE Healthcare, Lantheus Medical Imaging, Inc., Novartis AG, Point Biopharma, Positron Corp, Plus Therapeutics, Inc., Others, and Key Players |
| Pitfalls & Challenges: | COVID-19 Empact, Challenge, Future, Growth, & Analysis |
Get more details on this report -
Driving Factors
The development of new imaging technologies through positron emission tomography and single-photon emission computed tomography with advanced radiopharmaceuticals has created better diagnostic results and improved patient health outcomes. The market growth is driven by rising demand for personalized medicine and precision medicine which allows doctors to use specific treatments and develop customized medical plans. The combination of artificial intelligence with digital imaging systems improves operational processes and enables better data assessment and improved disease prediction capabilities. The healthcare market expansion occurs because developing countries build their medical facilities, and due to their beneficial insurance coverage systems and their supportive government rules.
Restraining Factors
The market for nuclear medicine is restricted by the high expense of radiopharmaceuticals and imaging equipment, strict regulatory approvals, a shortage of competent workers, and radiation safety issues, all of which conspire against extensive clinical integration and quick acceptance.
Market Segmentation
The North America nuclear medicine market share is classified into product type and application.
- The diagnostic radiopharmaceuticals segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.
The North America nuclear medicine market is segmented by product type into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals. Among these, the diagnostic radiopharmaceuticals segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The widespread use of PET and SPECT imaging, the growing incidence of chronic illnesses, and the growing need for prompt and precise diagnosis in neurology, cardiology, and oncology are the main factors driving the diagnostic radiopharmaceuticals market.
- The oncology segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
The North America nuclear medicine market is segmented by application into oncology, cardiology, neurology, and others. Among these, the oncology segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. The growing demand for precise diagnosis, disease monitoring, and focused treatment interventions in oncology, as well as the rising incidence of cancer and the broad use of PET and SPECT imaging, are the main drivers of the oncology application category.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the North America nuclear medicine market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Actinium Pharmaceuticals
- BWXT Medical
- Cardinal Health
- Cellectar Biosciences
- GE Healthcare
- Lantheus Medical Imaging, Inc.
- Novartis AG
- Point Biopharma
- Positron Corp
- Plus Therapeutics, Inc.
- Others
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Developments:
- In January 2025, GE HealthCare launched a strategic 7-year partnership with Sutter Health, serving 3.5 million patients in California, deploying AI-powered nuclear medicine imaging technologies, including PET/CT and SPECT/CT for advanced diagnostics.
Market Segment
This study forecasts revenue at the North America, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the North America nuclear medicine market based on the below-mentioned segments:
North America Nuclear Medicine Market, By Product type
- Diagnostic Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals
North America Nuclear Medicine Market, By Application
- Oncology
- Cardiology
- Neurology
- Others
Frequently Asked Questions (FAQ)
-
Q: What is the North America nuclear medicine market size?North America nuclear medicine market size is expected to grow from USD 6.29 billion in 2024 to USD 28.80 billion by 2035, growing at a CAGR of 14.83% during the forecast period 2025-2035.
-
Q: What are the key growth drivers of the market?Rising prevalence of chronic diseases, technological advancements, growing nuclear imaging applications, increasing healthcare expenditure, supportive government initiatives, and expanding awareness of early disease diagnosis.
-
Q: What factors restrain the North America nuclear medicine market?High equipment costs, regulatory challenges, limited skilled workforce, radiation safety concerns, reimbursement limitations, and competition from alternative imaging modalities like MRI and CT scans.
-
Q: How is the market segmented by product type?The market is segmented into radiopharmaceuticals, gamma cameras, PET scanners, SPECT scanners, hybrid imaging systems, and accessories, addressing diagnostic and therapeutic nuclear medicine applications.
-
Q: Who are the key players in the North America nuclear medicine market?Leading companies include GE Healthcare, Siemens Healthineers, Cardinal Health, Bracco Imaging, Curium Pharma, Lantheus Medical Imaging, and Jubilant Life Sciences, focusing on innovation and strategic collaborations.
-
Q: Who are the target audiences for this market report?Healthcare providers, pharmaceutical companies, radiology departments, medical device manufacturers, investors, research institutions, policymakers, and consultants seeking insights into nuclear medicine trends and growth opportunities.
Need help to buy this report?